FBLG · FibroBiologics Inc. Common Stock
View on chartInsiders & Stakes
| O'HEERON PETE Chief Executive Officer | ▲ Buy | Open Market | 5,958,147 Shares held | 3/4/2026 | View profile |
| Khoja Hamid Chief Scientific Officer | ▲ Buy | Grant | 301,571 Shares held | 9/15/2026 | View profile |
| GARCIA RUBEN A General Counsel | ▲ Buy | Open Market | 180,000 Shares held | 2/27/2026 | View profile |
| Davis Jason Chief Financial Officer | ▲ Buy | Open Market | 70,000 Shares held | 3/2/2026 | View profile |
Transaction History
| Khoja Hamid | ▲ Buy | Grant | 298,508 | $500K | 9/15/2026 |
| Khoja Hamid | ▲ Buy | Open Market | 30,000 | $11K | 3/4/2026 |
| O'HEERON PETE | ▲ Buy | Open Market | 15,872 | $6K | 3/4/2026 |
| O'HEERON PETE | ▲ Buy | Open Market | 18,200 | $7K | 3/3/2026 |
| O'HEERON PETE | ▲ Buy | Open Market | 17,428 | $6K | 3/2/2026 |
| Davis Jason | ▲ Buy | Open Market | 70,000 | $29K | 3/2/2026 |
| GARCIA RUBEN A | ▲ Buy | Open Market | 40,000 | $13K | 2/27/2026 |
| GARCIA RUBEN A | ▲ Buy | Open Market | 140,000 | $48K | 12/11/2025 |
| Khoja Hamid | ▲ Buy | Open Market | 20,000 | $17K | 5/27/2025 |
| O'HEERON PETE | ▼ Sell | Gift | 100,000 | $0 | 12/9/2024 |
| O'HEERON PETE | ▼ Sell | Gift | 50,000 | $0 | 12/3/2024 |
| O'HEERON PETE | ▲ Buy | Open Market | 8,500 | $16K | 8/12/2024 |
| Khoja Hamid | ▲ Buy | Open Market | 10,000 | $19K | 8/12/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
FibroBiologics Secures European Patent for Fibroblast Methods
FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.
FibroBiologics Secures European Patent for Fibroblast Methods. FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.